Last $2.99 USD
Change Today +0.04 / 1.36%
Volume 78.8K
ROSG On Other Exchanges
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $6.69
52 Week Low
12/9/14 - $2.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases; and a collaboration agreement with Biocept, Inc. to evaluate microRNAs from circulating tumor cells. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

45 Employees
Last Reported Date: 03/31/14
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosetta genomics ltd (ROSG) Key Developments

Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance

Rosetta Genomics Ltd. and Marina Biotech, Inc. jointly announced the initiation of the first project under the strategic alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD). In this study, Rosetta will evaluate archived muscle biopsy samples from 10-30 DMD patients and 10-30 non-DMD controls. The samples will be processed and assessed by Rosetta's microarray platform. Samples will also be profiled using deep sequencing to identify novel microRNAs and isomiRs.

Rosetta Genomics, Ltd. Presents at LD Micro Conference, Dec-03-2014 05:00 PM

Rosetta Genomics, Ltd. Presents at LD Micro Conference, Dec-03-2014 05:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Kenneth A. Berlin, Chief Executive Officer and President.

Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic

Rosetta Genomics Ltd. announced the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by EATRIS' new business model that brings together private industry and academia, and is the result of a partnering meeting held at the BIO USA 2014 convention in San Diego, California. Under this EATRIS private-public arrangement, the partners will work towards improving the diagnosis of malignant tumours in suspected thyroid cancer patients by connecting the expertise and clinical samples available at IMTM with the microRNA platform technology and product development expertise of Rosetta Genomics. An estimated 4% to 7% of the general population develops nodules in the thyroid that can be felt on examination, though fewer than 10% are malignant. Fine Needle Aspirate (FNA) to obtain tissue for analysis is the standard technique for detecting cancer. It is estimated that nearly 500,000 FNAs are performed each year in the U.S. and approximately 740,000 are performed annually in Europe. Interpretation of FNA samples is not always straightforward, leading to an indeterminate result in up to 30% of the samples. Many patients with indeterminate results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $2.99 USD +0.04

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $7.88 USD +0.14
Foundation Medicine Inc $47.26 USD -0.71
NeoGenomics Inc $3.89 USD +0.01
Response Genetics Inc $0.38 USD -0.0122
Veracyte Inc $7.94 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.6x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at